KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Free Cash Flow (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Free Cash Flow data on record, last reported at -$108.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 23.72% year-over-year to -$108.0 million; the TTM value through Dec 2025 reached -$269.1 million, up 50.74%, while the annual FY2025 figure was -$269.1 million, 50.74% up from the prior year.
  • Free Cash Flow reached -$108.0 million in Q4 2025 per IONS's latest filing, up from -$136.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $201.2 million in Q4 2021 and bottomed at -$204.3 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$70.9 million, with a median of -$108.7 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 564.24% in 2021, then soared 210.24% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $201.2 million in 2021, then crashed by 201.57% to -$204.3 million in 2022, then soared by 116.48% to $33.7 million in 2023, then crashed by 520.48% to -$141.6 million in 2024, then rose by 23.72% to -$108.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$108.0 million in Q4 2025, -$136.7 million in Q3 2025, and $139.0 million in Q2 2025.